Bristol Myers Squibb (CELG-RI) Capital Expenditures (2009 - 2026)
Bristol Myers Squibb (CELG-RI) posted quarterly Capital Expenditures of $305.0 million for Q2 2026, down 15.51% year-over-year from $361.0 million in Q2 2025, and down 12.1% quarter-over-quarter from $347.0 million in Q1 2026.
Bristol Myers Squibb (CELG-RI) Capital Expenditures (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has reported Capital Expenditures for 18 consecutive years, with $305.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Capital Expenditures fell 15.51% year-over-year to $305.0 million; the TTM figure through Jun 2026 stood at $1.3 billion (up 1.44% YoY), while the FY2025 annual figure was $1.3 billion, up 5.05% from the prior year.
- Capital Expenditures slipped to $305.0 million in Q2 2026 per CELG-RI's latest filing, from $347.0 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $378.0 million in Q4 2024 and bottomed at $247.0 million in Q3 2022.
- Historically, Capital Expenditures has averaged $307.7 million across 5 years, with a median of $312.5 million in 2025.
- Annual changes were most pronounced in 2022 — Capital Expenditures jumped 46.24% — and 2026, when it decreased 15.51%.
- Bristol Myers Squibb's Capital Expenditures stood at $346.0 million in 2022, then slipped by 4.62% to $330.0 million in 2023, then rose by 14.55% to $378.0 million in 2024, then fell by 2.12% to $370.0 million in 2025, then retreated by 17.57% to $305.0 million in 2026.
- Business Quant data shows CELG-RI's Capital Expenditures at $305.0 million in Q2 2026, $347.0 million in Q1 2026, and $370.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 1.32 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 322.00 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 893.00 Mn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 321.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 1.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 513.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 140.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 533.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -440.07 Mn |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | 305.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 305.00 Mn |
| Jun 30, 2026 | 305.00 Mn |
| Mar 31, 2026 | 347.00 Mn |
| Mar 31, 2026 | 347.00 Mn |
| Dec 31, 2025 | 370.00 Mn |
| Dec 31, 2025 | 370.00 Mn |
| Sep 30, 2025 | 320.00 Mn |
| Sep 30, 2025 | 320.00 Mn |
| Jun 30, 2025 | 361.00 Mn |
| Jun 30, 2025 | 361.00 Mn |
| Mar 31, 2025 | 260.00 Mn |
| Mar 31, 2025 | 260.00 Mn |
| Dec 31, 2024 | 378.00 Mn |
| Dec 31, 2024 | 378.00 Mn |
| Sep 30, 2024 | 324.00 Mn |
| Sep 30, 2024 | 324.00 Mn |
| Jun 30, 2024 | 262.00 Mn |
| Jun 30, 2024 | 262.00 Mn |
| Mar 31, 2024 | 284.00 Mn |
| Mar 31, 2024 | 284.00 Mn |